P Scheltens
Overview
Explore the profile of P Scheltens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
266
Citations
13037
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vijverberg E, de Haan W, Scheijbeler E, Hamby M, Catalano S, Scheltens P, et al.
J Prev Alzheimers Dis
. 2024 Nov;
11(6):1809-1817.
PMID: 39559892
Background: CT1812 is a first-in-class, sigma-2 receptor ligand, that prevents and displaces binding of amyloid beta (Aβ) oligomers. Normalization of quantitative electroencephalography (qEEG) markers suggests that CT1812 protects synapses from...
2.
Vermunt L, Sutphen C, Dicks E, de Leeuw D, Allegri R, Berman S, et al.
medRxiv
. 2023 Apr;
PMID: 37016671
Key Points: Abnormal levels of fluid markers for neuronal damage and inflammatory processes in CSF are associated with grey matter network disruptions.The strongest association was with NfL, suggesting that axonal...
3.
Exalto L, Boomsma J, Sep Y, Leeuwis A, Scheltens P, Biessels G, et al.
Cereb Circ Cogn Behav
. 2022 Nov;
3:100152.
PMID: 36324391
Background: Neuropsychiatric symptoms (NPS) are common in patients with vascular cognitive impairment (VCI). We aimed to establish sex differences in the manifestation of NPS in memory clinic patients with possible...
4.
Mofrad R, Del Campo M, Peeters C, Meeter L, Seelaar H, Koel-Simmelink M, et al.
Acta Neuropathol Commun
. 2022 Oct;
10(1):148.
PMID: 36273219
Background: Frontotemporal dementia (FTD) is caused by frontotemporal lobar degeneration (FTLD), characterized mainly by inclusions of Tau (FTLD-Tau) or TAR DNA binding43 (FTLD-TDP) proteins. Plasma biomarkers are strongly needed for...
5.
Singleton E, Pijnenburg Y, Gami-Patel P, Boon B, Bouwman F, Papma J, et al.
Alzheimers Res Ther
. 2022 Jan;
14(1):11.
PMID: 35057846
Background: The neurobiological origins of the early and predominant behavioral changes seen in the behavioral variant of Alzheimer's disease (bvAD) remain unclear. A selective loss of Von Economo neurons (VENs)...
6.
Scheltens P, Vijverberg E
J Prev Alzheimers Dis
. 2021 Sep;
8(4):412-413.
PMID: 34585214
No abstract available.
7.
Willemse E, Scheltens P, Teunissen C, Vijverberg E
Alzheimers Res Ther
. 2021 May;
13(1):101.
PMID: 34006321
Background: Neurofilament light in serum (sNfL) is a biomarker for axonal damage with elevated levels in many neurological disorders, including neurodegenerative dementias. Since within-group variation of sNfL is large and...
8.
van de Beek M, van Steenoven I, van der Zande J, Porcelijn I, Barkhof F, Stam C, et al.
Alzheimers Res Ther
. 2021 Feb;
13(1):53.
PMID: 33637117
Background: The DEmEntia with LEwy bOdies Project (DEvELOP) aims to phenotype patients with dementia with Lewy bodies (DLB) and study the symptoms and biomarkers over time. Here, we describe the...
9.
Ebenau J, Verfaillie S, van den Bosch K, Timmers T, Wesselman L, van Leeuwenstijn M, et al.
Eur J Nucl Med Mol Imaging
. 2020 Sep;
48(3):747-756.
PMID: 32888039
Purpose: To determine thresholds for amyloid beta pathology and evaluate associations with longitudinal memory performance with the aim to identify a grey zone of early amyloid beta accumulation and investigate...
10.
Wesselman L, Schild A, Hooghiemstra A, Meiberth D, Drijver A, Leeuwenstijn-Koopman M, et al.
J Prev Alzheimers Dis
. 2020 May;
7(3):184-194.
PMID: 32463072
Background: Online programs targeting lifestyle have the potential to benefit brain health. We aimed to develop such a program for individuals with subjective cognitive decline (SCD). These individuals were reported...